Skip to main content

REVIEW article

Front. Immunol.
Sec. NK and Innate Lymphoid Cell Biology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1466266
This article is part of the Research Topic Community Series in : Innate Lymphoid Cells in Cancer: Volume II View all articles

Potential of gamma/delta T cells for solid tumor immunotherapy

Provisionally accepted
Dantong Zhu Dantong Zhu 1Xijing Ren Xijing Ren 1,2Wanting Xie Wanting Xie 3Jianjun Chen Jianjun Chen 1Shiying Liang Shiying Liang 1,2Mingzhe Jiang Mingzhe Jiang 1Junyi Wang Junyi Wang 1Zhendong Zheng Zhendong Zheng 1*
  • 1 Oncology department, General Hospital of Northern Theater Command, Shenyang,Liaoning, China
  • 2 Shenyang Pharmaceutical University, Shenyang, Liaoning Province, China
  • 3 Nursing department, General Hospital of Northern Theater Command, Shenyang,Liaoning, China

The final, formatted version of the article will be published soon.

    Gamma/delta T (γδ T)cells possess a unique mechanism for killing tumors, making them highly promising and distinguished among various cell therapies for tumor treatment. This review focuses on the major histocompatibility complex (MHC)-independent recognition of antigens and the interaction between γδ T cells and solid tumor cells. A comprehensive review is provided regarding the classification of human gamma-delta T cell subtypes, the characteristics and mechanisms underlying their functions, as well as their regulatory effects on tumor cells. The involvement of γδ T cells in tumorigenesis and migration was also investigated, encompassing potential therapeutic targets such as apoptosis-related molecules, the TNF receptor superfamily member 6(FAS)/FAS Ligand (FASL) pathways, butyrophilin 3A-butyrophilin 2A1 (BTN3A-BTN2A1) complexes, and interactions with CD4, CD8, and natural killer (NK) cells. Additionally, immune checkpoint inhibitors such as programmed cell death protein 1/Programmed cell death 1 ligand 1 (PD-1/PD-L1) have the potential to augment the cytotoxicity of γδ T cells.Moreover, a review on gamma-delta T cell therapy products and their corresponding clinical trials reveals that chimeric antigen receptor (CAR) gamma-delta T therapy holds promise as an approach with encouraging preclinical outcomes. However, practical issues pertaining to manufacturing and clinical aspects need resolution, and further research is required to investigate the long-term clinical side effects of CAR T cells. In conclusion, more comprehensive studies are necessary to establish standardized treatment protocols aimed at enhancing the quality of life and survival rates among tumor patients utilizing γδ T cell immunotherapy.

    Keywords: Gamma delta T, Immunotherapy, Solid tumor, adoptive cell therapy, car-t

    Received: 17 Jul 2024; Accepted: 06 Aug 2024.

    Copyright: © 2024 Zhu, Ren, Xie, Chen, Liang, Jiang, Wang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zhendong Zheng, Oncology department, General Hospital of Northern Theater Command, Shenyang,Liaoning, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.